porter so that FU is translocated into the tubular lumen. Henle [1, 6] . Coadministration of FU with intravenous as compared with the HA infusion alone (118 Ϯ 12 mmol, 1827 Ϯ albumin could theoretically improve delivery and the 141 ml). The coadministration of FU and HA caused an even natriuretic effect of FU, that is, change the pharmacokimore marked increase (P Ͻ 0.01 vs. HA alone) of urinary sodium (312 Ϯ 28 mmol) and volume excretion (3230 Ϯ 201 netics of FU. This approach has been shown to restore ml); the difference to FU administration alone was significant the natriuretic action of FU in analbuminemic nephrotic (P Ͻ 0.05). Plasma atrial natriuretic factor, serum albumin rats [3] . In addition, albumin infusion may increase the concentration, and urinary albumin excretion increased signatriuretic effect of FU via other mechanisms, including nificantly on both HA infusion days, whereas urinary excretion of FU remained unchanged with HA coadministration. Gloreversal of absolute or relative hypovolemia, and tranmerular filtration rate (C In ) was not significantly affected by sient reversal of sodium-conserving neural or humoral any of the infusion protocols, but effective renal plasma flow mechanisms. In view of the many potential mechanisms, (C PAH ) increased significantly on both HA infusion days.
it is not surprising that in humans the effect of coadminisConclusions. Coadministration of HA potentiates the action of FU in patients with the nephrotic syndrome, but only modtration is controversial [4, [8] [9] [10] [11] [12] . The reasons for the estly. This effect is mediated by changes in renal hemodynamics.
variability of results may include differences in volume status, renal function, type of disease causing the nephrotic syndrome, etc. [13, 14] . In patients with the nephrotic syndrome, the natriuretic This double-blind, randomized, placebo-controlled effect of furosemide (FU) is thought to be diminished cross-over study was designed to compare the diuretic and natriuretic effects of intravenous FU in combination with an infusion of human albumin (HA) or a sham
METHODS
Langen, Germany), and (c) a sham infusion (50 ml of a 0.9% NaCl solution) plus 200 ml of a 20% solution of Patients HA. The patients were allocated to the different treatAll consecutive patients who agreed to participate (by ment sequences using random numbers. The intravenous written informed consent) and who met the entry criteria route of FU administration was chosen to avoid potential were included into the study. Entry criteria included:
interference with intestinal absorption. The dose of 40 urinary protein excretion above 3.5 g/24 hr (that is, neg of HA (200 ml of a 20% solution) was chosen in order phrotic range proteinuria), primary renal disease (the to avoid a supranormal oncotic pressure [15] . absence of amyloidosis or other systemic diseases), and
Patients were examined in a quiet environment while a defined glomerular histology to minimize the heterogein a recumbent position. They fasted during the first 10 neity of underlying conditions (6 patients had biopsyhours (from 8 a.m. to 6 p.m.); afterward, they were up proven membranous glomerulonephritis and 3 minimal and about. The infusions mentioned earlier here were change glomerulonephritis/focal-segmental glomerulogiven at 10 a.m. over a period of 60 minutes. Mean sclerosis). Routine blood chemistry and urine analysis arterial pressure (MAP) was measured at regular interwere performed at entry into the study. Nine patients vals before drug administration and thereafter. The pawere studied ( and FU excretions were assessed in the urine samples. the renal function was within the normal range (serum To achieve a steady state of urine flow, patients drank creatinine concentration below 1.3 mg/dl) and the mean a quantity of tap water that matched the urine volume glomerular filtration rate (GFR) was 105 Ϯ 9 ml/min/ passed in the preceding period. GFR and effective renal 1.73 m 2 . All patients had been on diuretic medication, plasma flow were assessed using the inulin (C In ) and and this was withdrawn for at least one week prior to the paraaminohippurate (C PAH ) clearance methods as destart of the study. At study entry, moderate (ϩϩ) to scribed elsewhere [16] . In brief, a priming dose of 1500 marked (ϩϩϩ) edema was present in all patients. Antihymg inulin/m 2 (Inutest; Laevosan Co., Linz, Austria) and pertensive drugs (if present) were not washed out, but 500 mg PAH/m 2 (Nephrotest; Biologische Arbeitsgetheir dosage was kept unchanged throughout the study.
meinschaft GmbH, Lich, Germany) was given at 8 a.m.
Protocol
The bolus injection was followed by continuous infusions of inulin (10 mg/m 2 /min) and PAH (8 mg/m 2 /min) mainThe protocol of this study was approved by the Ethics tained with ultraprecise pumps (Perfusor FT; Braun Committee of the University of Heidelberg. A doubleMelsungen, Melsungen, Germany) from 8 a.m. to 6 p.m. blind, placebo-controlled cross-over design was used. For Both the bolus injection and the continuous infusions of 10 days, patients adhered to a diet containing a standardinulin and PAH were administered in 0.9% NaCl soluized amount of sodium chloride. The diet was prepared tion. The amount of sodium chloride administered with as precooked, deep-frozen meals with a standardized the infusions was identical on all study days. After a 120-sodium content of 20 mmol/day (low-salt diet). To minute equilibration period (from 8 a.m. to 10 a.m.), achieve a final daily sodium intake of approximately 80 blood samples for measurements of GFR and effective mmol, the diet was supplemented with six slow-release renal plasma flow were withdrawn at regular intervals salt tablets (Ciba-Geigy, London, UK), each containing until 6 p.m. In addition, blood samples for the measure-10 mmol of sodium. Dietary compliance was controlled ment of atrial natriuretic factor (ANF) and serum albuby regular measurements of 24-hour urinary sodium exmin concentration were withdrawn at 10 a.m., 12 a.m., cretion. In addition, patients were instructed to keep and 4 p.m. Body weight was measured on all study days. their daily fluid intake constant, that is, to drink approximately 2 liters of tap water. They were also advised to Measurements and calculations refrain from taking a sauna, doing any sporting activity Plasma and urine sodium concentrations were meaor unaccustomed physical exertion for the period of the sured with flame photometry (Eppendorf 5051; Hamstudy. On the fifth, seventh, and ninth study days, paburg, Germany), and serum and urine albumin concentients were given in random order the following infutrations with nephelometry (Array Protein System; sions: (a) 60 mg of FU (Lasix; Hoechst AG, Frankfurt, Beckmann Instruments, Munich, Germany). Plasma Germany) dissolved in 50 ml of a 0.9% NaCl solution, concentration of ANF was measured with radioimmunoplus a sham infusion (200 ml of aqua ad iniectabilia), assay, the concentration of FU in urine with fluorometry (b) 60 mg of FU dissolved in 50 ml of a 0.9% NaCl and high-performance liquid chromatography. Urine solution plus 200 ml of a 20% solution of HA (NormalSerum-Albumin Alpha 20%; Alpha Therapeutic GmbH, samples were collected in light-protected tubes because 
Statistics
The predetermined primary efficacy parameters were multiple comparisons of related data. If this test gave a the differences of mean urinary sodium and volume exsignificant difference between treatments, a two-sided cretions in the first eight hours after the start of infusions Wilcoxon test for paired data was applied to compare the between the following protocols: (a) administration of respective treatments. Other parameters were compared FU plus sham infusion, (b) administration of FU plus using the previously mentioned tests. Differences were infusion of HA, and (c) sham administration plus infuaccepted as statistically significant at a P level of 0.05. sion of HA. Data were evaluated with the SPSS program using the Friedman test, that is, a nonparametric test for Data are shown as mean Ϯ sem. This study in patients with the nephrotic syndrome significantly with the administration of HA (Table 1) . documents a modest but significant increase in urinary The patients lost on average a total of approximately volume and sodium chloride excretion when HA was 500 mmol sodium during the six-day study period (that coadministered with FU as compared with administrais, urinary sodium excretion minus dietary intake plus tion of a submaximal dose of FU alone. Furthermore, sodium infused on the study days). Because of the ranthe study identifies some mechanisms underlying the domization of our patients to the different treatments, stimulatory effect of albumin coadministration on natrithe mean 24-hour sodium excretion in the days after the uresis, that is, volume expansion (as documented by an studies was similar with all treatments (82 Ϯ 11 mmol, increase of plasma ANF concentration) with a concomi-HA ϩ sham; 83 Ϯ 12 mmol, FU ϩ sham; and 80 Ϯ 14 tant increase in renal plasma flow. We admit that we mmol, FU ϩ HA). The same was true for mean 24-hour did not measure PAH extraction; we cannot definitely urinary volume excretion (2098 Ϯ 351 ml, HA ϩ sham;
exclude, but consider it unlikely, that there was a change 1968 Ϯ 374 ml, FU ϩ sham; and 1953 Ϯ 387 ml, FU ϩ in PAH extraction with no change in renal plasma flow. HA), the mean patient body weight (78 Ϯ 6 kg, HA ϩ Our findings are compatible with the view that the effect sham; 78 Ϯ 6 kg, FU ϩ sham; and 78 Ϯ 6 kg, FU ϩ HA), of albumin is mainly mediated via a change in intrarenal as well as the average MAP (at 10 a.m. of the three study hemodynamics. A direct effect of increased ANF condays; 100 Ϯ 2 mm Hg, FU ϩ HA; 103 Ϯ 2 mm Hg, centrations on tubular sodium reabsorption after albu-FU ϩ sham; and 99 Ϯ 2 mm Hg, HA ϩ sham). As a min infusion, as suggested by some studies [19, 20] , is consequence of the modest cumulative sodium loss durless plausible because most studies found resistance to ing the six-day study period, the mean plasma sodium the action of ANF in the nephrotic syndrome [13] . concentration in our nine patients decreased from 141 Ϯ 1
The assumption that intrarenal mechanisms are mainly to 135 Ϯ 1 mmol/liter, and body weight decreased from responsible for the greater natriuretic response to albu-79 Ϯ 6 to 76 Ϯ 6 kg from study day 5 to study day 10. min coadministration is further corroborated by the ob- Table 3 gives individual data on infusions administered, servation that albumin coadministration did not change body weight, blood pressure, and plasma sodium concentration on study days 5, 7, and 9.
the pattern of urinary FU excretion with time and the Table 3 . Individual data on randomization, body weight, blood pressure and plasma sodium concentration on 5th, 7th and 9th study day in 9 patients with nephrotic syndrome Patient 5th day 7th day 9th day cumulative urinary FU excretion at eight hours in these concentrations. This is in line with previous observations, moderately hypoproteinemic patients. Although the exwhich documented that nephrotic patients can accommoperiments of Inoue et al suggested the possibility that date substantial volume loads without an increase in albumin infusion might increase FU delivery into tubular blood pressure [21] . It therefore seems relatively safe to urine [3] , we conclude that in our study conditions the administer albumin even in severely nephrotic patients. albumin infusion does not alter the pharmacokinetics How do our results compare with other controlled but definitely affects the pharmacodynamics of FU. We studies concerning the administration of albumin plus cannot exclude, however, that the amount of unbound FU in patients with nephrotic syndrome? Previous stud-(pharmacologically active) FU measured in the urine ies did not provide measurements of ANF [4, 11] or does not correspond to the active (unbound) FU at its renal clearances [11] . The patients studied were also site of action [5] .
heterogeneous with respect to the underlying renal disIt was our intention to assess the mechanisms underlying ease, and in addition, most of these patients had impaired the potentially higher efficacy of combination treatment renal function. Sjö strö m et al administered 40 mg of FU in order to provide rational guidelines for the treatment and found an increase of cumulative sodium excretion of therapy-resistant nephrotic syndrome. This intention of approximately 15% with infusion of either albumin precluded the investigation of severely morbid patients, or the volume expander dextran [4] ; patients given albuwho cannot be maintained in a stable condition without min or dextran excreted exactly the amount of NaCl permanent administration of diuretics, and the diuretics that had been administered. In contrast, Akcicek et al affect the steady state because of rebound phenomenon, administered 1 mg FU per minute, that is, a maximal fluctuations in volume status, etc. Consequently, our dose, to severely edematous nephrotic patients [11] . findings cannot necessarily be extrapolated to patients They failed to see a further increase of sodium excretion with more extreme degrees of nephrotic syndrome and with coadministration of 0.5 g albumin/kg. It is notable hypoalbuminemia. We emphasize, however, that coadthat this FU dose had increased sodium excretion from ministration of FU and albumin caused a larger diuresis 15 to 934 mol/min, which is a substantial proportion of and natriuresis than FU alone, even in the patient with the filtered load. It would have been difficult to achieve the highest urinary protein excretion (17.8 g/day) and any further increment. the lowest serum albumin concentration (18.1 g/liter;
As to the clinical management of patients with ne- Fig. 1 ). Because we did not have a fourth study arm with phrotic syndrome, it emerges from our study, as well as sham infusion for FU and sham infusion for albumin, two others [4, 11] , that it is more sensible to increase the issue of whether the effect of albumin and FU was the dose of FU than to infuse albumin. Our findings lend additive or even interactive cannot be addressed. A modcredence to numerous uncontrolled clinical observations estly negative sodium balance was observed in our pathat coadministration of albumin increases the natritients during the six-day study period. We emphasize, uretic potency of FU at least at submaximal doses [8-10], however, that the randomized assignment to different but does not directly address the issue of whether the treatment arms should have eliminated any systematic same is still true at maximal doses of FU. A potential change related to differences in total sodium stores.
drawback of this approach (besides the cost) is the short We observed no side effects. It is of note that in our duration of albumin's action, as the increase in urinary patients, blood pressure did not increase after infusion volume and sodium excretion with the combination of albumin despite an increase in blood volume after infusion of albumin, as documented by increased ANF treatment compared with FU monotherapy was noted
